Takeda

News

FDA to decide on Takeda's psoriasis blockbuster hope in Q1

The FDA has started a review of the marketing application for Takeda's TYK2 inhibitor zasocitinib in psoriasis, setting up a decision in mid-March.

News

Andy Plump to step down as Takeda's R&D chief

Andy Plump, credited with a 'soup-to-nuts' overhaul of Takeda's R&D in more than a decade of leadership at the division, has announced his retirement.

News

FDA clears Takeda, Protagonist's first-in-class PV drug

Takeda and Protagonist's hepcidin mimetic rusfertide is the first hepcidin mimetic to be approved by the FDA for blood cancer polycythaemia vera.

News

Takeda's first-in-class narcolepsy drug claims FDA approval

Takeda's orexin agonist Orzeyful is the first drug approved in the US that can treat the "full range" of narcolepsy type 1 symptoms, says the FDA.

News

Takeda gets first OK for orexin narcolepsy drug, in China

China has become the first country to approve Takeda's first-in-class orexin agonist, oveporexton, for the sleep disorder narcolepsy.

News

Takeda's TYK2 drug bests BMS's Sotyktu in psoriasis contest

New data with Takeda's TYK2 inhibitor zasocitinib suggest it is significantly more effective than BMS's Sotyktu in the treatment of psoriasis.

FDA to decide on Takeda's psoriasis blockbuster hope in Q1

Andy Plump to step down as Takeda's R&D chief

FDA clears Takeda, Protagonist's first-in-class PV drug

Takeda's first-in-class narcolepsy drug claims FDA approval

Takeda gets first OK for orexin narcolepsy drug, in China

Takeda's TYK2 drug bests BMS's Sotyktu in psoriasis contest

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

Takeda

Editor's Picks